AMMON LOTT: Open Payments
NPI 1902489032 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$289 in 16 payments from 8 companies in 2025. Trend: 2023 $260 · 2024 $364 · 2025 $289
Food & beverage: $289
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Lilly USA, LLC | 3 | $45 |
| Novartis Pharmaceuticals Corporation | 1 | $31 |
| Organon LLC | 2 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Novo Nordisk Inc | 1 | $18 |
| SANOFI-AVENTIS U.S. LLC | 1 | $17 |
Products named: QULIPTA, REXULTI, MOUNJARO, LEQVIO, NEXPLANON, UBRELVY, XIFAXAN, Ozempic.
Industry payments across UT — which companies pay providers there.
